News | October 24, 2025
Laurus Labs posts Q2 FY26 consolidated PAT higher at Rs. 195 Cr
Laurus Labs has reported total income of Rs. 1,680.43 crore during the period ended September 30, 2025
Laurus Labs has reported total income of Rs. 1,680.43 crore during the period ended September 30, 2025
_256_384.jpg)
Tirzepatide is a prescription based the first and only dual agonist of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors
The product is indicated for the chronic management of patients with Urea Cycle Disorders
Yesintek and Yesintek I.V. are approved for the treatment of moderate to severe plaque psoriasis in adults and pediatric patients
Glenmark’s Ropivacaine Hydrochloride Injection USP is bioequivalent and therapeutically equivalent to the reference listed drug Naropin Injection of Fresenius Kabi USA
The submissions are supported by data from the Phase 3 KEYNOTE-905 trial
Global Phase 3 MANEUVER study highlights ongoing benefits and consistent safety profile
Vamikibart is the first targeted, non-steroid treatment designed to address the underlying inflammation driving UME
Gazyva/Gazyvaro is the only anti-CD20 monoclonal antibody to demonstrate a complete renal response benefit in lupus nephritis in a randomised phase III study
Adding one year of Imfinzi treatment to Bacillus Calmette-Guérin (BCG) induction and maintenance therapy delivered an early and sustained disease-free survival benefit vs. BCG alone
Subscribe To Our Newsletter & Stay Updated
